Ultra low dose thalidomide in myeloma revisited
نویسندگان
چکیده
منابع مشابه
Low-dose thalidomide in myeloma: efficacy and biologic significance.
The efficacy of thalidomide at doses as low as 50 mg every other day was first reported at the VII International Multiple Myeloma Workshop in Stockholm, Sweden, in September 1999. This article discusses the duration of responses with low-dose thalidomide and the subsequent efficacy with thalidomide combination approaches. The median effective dose of thalidomide was 200 mg/d. Thalidomide's mech...
متن کاملEfficacy of a low dose of thalidomide in advanced multiple myeloma.
blood products administered to the patients who became SENV-H PCR–positive postoperatively (median, 108 U) and to the ones who remained PCR negative (median, 140 U). The prevalence of SENV-H viremia in Japanese blood donors was shown to vary from 2% to about 10%.1,2 Based on these data, each patient should have received 2 to 14 SENV-H–positive units of blood products. This could explain the obs...
متن کاملEfficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma.
PURPOSE The efficacy of low-dose thalidomide (THAL) plus dexamethasone (DEX) has been evaluated in myeloma. The clinical outcome of patients treated with THAL-DEX was compared with that of a control group treated with conventional chemotherapy (CC). EXPERIMENTAL DESIGN A total of 120 relapsed/refractory patients to one (52%), or two or more(48%) lines of chemotherapy were treated with THAL 10...
متن کاملbortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
normal 0 false false false en-us x-none fa background : the aim of the study was to assess the effects of combination of bortezomib moderate dose and continuous oral low dose melphalan and thalidomide and dexamethasone (bmtd regimen) in elderly patients aged ≥ 65 years with relapsed multiple myeloma (mm). methods : twenty four patients with advanced mm were enrolled to receive eight 3-week trea...
متن کاملLow-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.
BACKGROUND AND OBJECTIVES The immunomodulatory drug thalidomide can inhibit angiogenesis and induce apoptosis in experimental models. It can also induce marked and durable response in advanced myeloma patients. Thalidomide has been used at doses ranging from 200 to 800 mg with significant toxicity. No data are available on the impact of low-dose thalidomide plus dexamethasone as salvage therapy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2010
ISSN: 0007-1048,1365-2141
DOI: 10.1111/j.1365-2141.2010.08182.x